Skip to content

Comparison of the Effect of A-PRF and L-PRF on Outcomes After Removal of Impacted Mandibular Third Molar

Comparison of the Effect of Advanced Platelet-rich Fibrin and Leukocyte- and Platelet-rich Fibrin on Outcomes After Removal of Impacted Mandibular Third Molar: A Randomised Split-mouth Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03672669
Enrollment
27
Registered
2018-09-14
Start date
2017-11-05
Completion date
2018-05-20
Last updated
2018-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Trismus, Swelling

Keywords

Leukocyte- and platelet rich fibrin, Advanced platelet rich fibrin, Impacted mandibular third molar surgery

Brief summary

In this study, it was aimed to investigating and comparing the postoperative effects of leukocyte- and platelet-rich fibrin (L-PRF) and advanced platelet-rich fibrin (A-PRF) in terms of pain, swelling on the cheek, and trismus after mandibular third molar surgery. The study included a total of 27 patients with bilateral impacted mandibular third molar which surgically operated at different times. Patients were evaluated in two randomly separated groups. For the first group; A-PRF and for the second group; L-PRF was applied into the tooth socket. The outcomes variables were; pain, swelling, the number of analgesics taken, and trismus. These variables were also assessed on the basis of; 1st, 2nd, 3rd and 7th days following the operation.

Interventions

blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF

GENETICLeukocyte- and platelet-rich fibrin (L-PRF)

blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF

Sponsors

Near East University, Turkey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

patients with bilateral impacted mandibular third molar which surgically operated at different times

Eligibility

Sex/Gender
ALL
Age
18 Years to 26 Years
Healthy volunteers
Yes

Inclusion criteria

* age≥18 * the presence of bilaterally symmetrically impacted mandibular third molar, which requires an extraction for prophylactic reasons * absence of systemic diseases * absence of chronic opioid taken; * not being pregnant * not smoking and no alcohol usage * the absence of allergy to penicillin or any other drugs used during standardized postoperative therapy.

Exclusion criteria

* tooth needed to be sectioning during the operation * operation time exceeding 30 minutes * the cases with severe periodontal disease or acute pericoronitis, * the cases using antibiotics for an existing infection * the cases not capable of following postoperative instructions

Design outcomes

Primary

MeasureTime frameDescription
Pain Scores Evaluted1st day after the operation.For the postoperative period, the pain scores change was evaluated with the help of the visual analog scale (VAS) ranging from 0 (no pain) to 10 (most severe pain).

Secondary

MeasureTime frameDescription
Number of Analgesics Taken by the PatientsEach patient was evaluated on the 1st, 2nd, 3rd, and 7th days after the operation.
TrismusEach patient was evaluated in order to obtain measurements on the 1st, 2nd, 3rd, and 7th days after the operation.Trismus was assessed by measuring the distance between the mesioincisal corner of the maxillary and mandibular right incisors while mouth was fully opened
Swelling on the cheekEach patient was evaluated in order to obtain measurements on the 1st, 2nd, 3rd, and 7th days after the operation.In order to record swelling, a modification of the tape measurement method

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026